HMDCF OTC
HUTCHMED (China) Limited
1W: -23.4%
1M: -23.4%
3M: -28.5%
YTD: -41.0%
1Y: -32.5%
3Y: -45.3%
5Y: -57.7%
$2.16
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.9B
52W Range2.16-3.815
Volume468
Avg Volume29
Beta0.38
Dividend—
Analyst Ratings
Company Info
CEOChig Fung Cheng
Employees1,811
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2014-04-17
Websitehutch-med.com
Cheung Kong Center
Hong Kong
HK
Hong Kong
HK
852 2128 1188
About HUTCHMED (China) Limited
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.
Latest News
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
Recent Insider Trades
No insider trades found